Cantor Fitzgerald Issues Negative Forecast for PRQR Earnings

ProQR Therapeutics (NASDAQ:PRQR - Free Report) - Stock analysts at Cantor Fitzgerald decreased their FY2025 earnings per share (EPS) estimates for shares of ProQR Therapeutics in a note issued to investors on Monday, May 12th. Cantor Fitzgerald analyst S. Seedhouse now anticipates that the biopharmaceutical company will post earnings per share of ($0.43) for the year, down from their prior estimate of ($0.39). Cantor Fitzgerald has a "Overweight" rating and a $8.00 price objective on the stock. The consensus estimate for ProQR Therapeutics' current full-year earnings is ($0.31) per share.

PRQR has been the subject of several other research reports. HC Wainwright increased their price objective on shares of ProQR Therapeutics from $10.00 to $12.00 and gave the company a "buy" rating in a research note on Friday, March 14th. Oppenheimer decreased their price objective on shares of ProQR Therapeutics from $15.00 to $9.00 and set an "outperform" rating for the company in a research note on Tuesday, May 13th. Chardan Capital reiterated a "buy" rating and issued a $4.00 price objective on shares of ProQR Therapeutics in a research note on Friday, March 14th. Citigroup upgraded shares of ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 price target for the company in a research note on Monday, March 10th. Finally, Evercore ISI initiated coverage on shares of ProQR Therapeutics in a research note on Tuesday, April 29th. They set an "outperform" rating and a $5.00 price target for the company. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, ProQR Therapeutics has an average rating of "Moderate Buy" and an average target price of $8.00.

ProQR Therapeutics Stock Performance

NASDAQ:PRQR traded up $0.05 on Wednesday, hitting $1.67. The stock had a trading volume of 180,013 shares, compared to its average volume of 624,589. The stock has a market cap of $175.60 million, a P/E ratio of -5.22 and a beta of 0.35. ProQR Therapeutics has a 1 year low of $1.07 and a 1 year high of $4.62. The firm's fifty day simple moving average is $1.46 and its two-hundred day simple moving average is $2.33.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.02). ProQR Therapeutics had a negative net margin of 134.31% and a negative return on equity of 71.58%. The business had revenue of $4.89 million during the quarter, compared to the consensus estimate of $4.90 million.

Institutional Investors Weigh In On ProQR Therapeutics

A number of institutional investors have recently made changes to their positions in the company. Bank of America Corp DE grew its holdings in shares of ProQR Therapeutics by 11.8% during the fourth quarter. Bank of America Corp DE now owns 81,784 shares of the biopharmaceutical company's stock valued at $217,000 after buying an additional 8,621 shares during the last quarter. Jane Street Group LLC purchased a new stake in shares of ProQR Therapeutics during the fourth quarter valued at approximately $30,000. Squarepoint Ops LLC grew its holdings in shares of ProQR Therapeutics by 16.3% during the fourth quarter. Squarepoint Ops LLC now owns 83,114 shares of the biopharmaceutical company's stock valued at $220,000 after buying an additional 11,623 shares during the last quarter. Invesco Ltd. purchased a new stake in shares of ProQR Therapeutics during the fourth quarter valued at approximately $32,000. Finally, OneDigital Investment Advisors LLC grew its holdings in shares of ProQR Therapeutics by 45.5% during the first quarter. OneDigital Investment Advisors LLC now owns 40,000 shares of the biopharmaceutical company's stock valued at $53,000 after buying an additional 12,500 shares during the last quarter. Hedge funds and other institutional investors own 32.65% of the company's stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).